Slides
Page 1
Annual General Meeting 18 November 2025 For personal use only
Page 2
Artwork by Charmaine Mumbulla For personal use only
Page 3
Page 2 Introduction to Board Directors Graham Hodges Chair and Independent Non-Executive Director Dr Linda Mellors Managing Director and Chief Executive Officer Ian Roberts Non-Executive Director Prof Christine Bennett AO Independent Non-Executive Director Sally Freeman Independent Non-Executive Director Jodie Leonard Independent Non-Executive Director For personal use only
Page 4
Agenda 1. Chair’s Address 2. CEO’s Address 3. Formal Business 4. Closing For personal use only
Page 5
Chair’s Address For personal use only
Page 6
Page 5 A Leading Provider of High-Quality Aged Care Residential Aged Care Residential Aged Care - Development Site Home Care, Day Respite and Therapy Centre Retirement Living 31 2 3 1 6 2 19 5 3 3 4 1 4 8 2 1 3 30+ years of care and support ~8,200 available beds (31 October 2025)1 72 aged care homes1 (100% freehold ownership) and 9 development sites ~13,000 employees 96.5% mature homes spot occupancy2 (31 October 2025) ~10,000 residents and clients 93% single rooms as a percentage of total rooms 1 4 ___________________ 1 Includes Rockpool acquisition (4 homes, 600 beds) completed on 1 September 2025. Excludes OC Health acquisition (2 homes, 230 beds) expected to complete on 1 December 2025 2 Mature homes occupancy excludes Regis Camberwell (112 beds) and Regis Oxley (150 beds) For personal use only
Page 7
Page 6 Financial Performance Overview 701.4 725.3 780.6 1,014.1 1,161.3 FY21 FY22 FY23 FY24 FY25 Revenue from Services ($m) 72.1 78.1 83.3 107.2 125.8 FY21 FY22 FY23 FY24 FY25 Underlying EBITDA ($m) (142.4) (102.9) (6.0) 64.9 192.5 FY21 FY22 FY23 FY24 FY25 Net Cash / (Debt) ($m) 6.63 5.84 9.48 12.92 16.22 FY21 FY22 FY23 FY24 FY25 Dividends (cps) For personal use only
Page 8
Page 7 Ageing Population with Undersupply of Beds 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 % Pop 85+ Pop 85+ Australia's Ageing Population - Australians 85+1 Pop 85+ % Pop 85+ ___________________ 1 Centre of Population Ageing Research (CEPAR) - population projections for Australia and the States and Territories 2 Australian Institute of Health and Welfare - GEN Aged Care Data - Aged care data snapshots 6,453 6,255 3,748 1,960 860 1,502 2,224 802 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 Net annual movement in sector beds2 ~5,400 net new beds last 4 years Projected future demand: ~9,300 net new beds needed per year For personal use only
Page 9
Page 8 Sector Funding Care ► AN-ACC + Supplements ► Non-clinical care contribution (previously means tested care fee) ► Other direct care revenue Everyday Living ► Basic daily fee ► Hotelling supplement ► Higher everyday living fee (previously additional services and extra services) Accommodation ► Accommodation supplement ► RAD retention ► DAP payments Operating Revenue Changes needed ► Funding should be reviewed at a holistic level ► Provision of an appropriate care margin ► Full funding of everyday living expenses ► Additional accommodation funding to incentivise new builds. For example: • Increased RAD retention rate from 2% to 4% • Significant increase in the accommodation supplement to address the current imbalance between supported and non-supported residents: - Immediate increase of $10 per resident per day - Additional $40 per resident per day to improve equity across resident categories - Further $20 per resident per day for residents in newly built facilities to encourage development • MPIR replaced by sector WACC For personal use only
Page 10
CEO’s Address For personal use only
Page 11
Page 10 FY25 Recap Revenue from Services $1,161.3m Average Occupancy 95.6% Underlying EBITDA $125.8m Average Overall Star Rating 3.78 Net Operating Cash Flow $306.1m Underlying NPAT $53.4m Net Cash Results Overview ► Revenue from services of $1,161.3 million, up 14.5% on pcp ► Underlying EBITDA of $125.8 million, up 17.4% on pcp ► Underlying EBIT of $77.3 million, up 25.7% on pcp ► Underlying NPAT of $53.4 million, up 37.3% on pcp • Excludes $4.4 million of one-off items (after tax) ► Net cash of $192.5 million, up 196.6% on pcp ► Final dividend of 8.13 cents per ordinary share (70% franked) • Total FY25 dividends of 16.22 cents per ordinary share represents 100% of FY25 NPAT Operational Highlights ► Mature homes average occupancy of 95.6%, up from 94.1% in pcp ► Acquisitions - Ti Tree (December 2024), BodeWell (April 2025) $192.5m Final Dividend 8.13c Net RAD Cash Inflow $195.4m Average Care Minutes 226.7 For personal use only
Page 12
Page 11 New Aged Care Act - 1 November 2025 Funding ► Care • Government to continue to fund clinical care costs for residents • Independent pricing body (IHACPA) will continue to advise Government ► Everyday living • Residents with means will co-contribute towards non-clinical care and everyday living ► Accommodation • Re-introduction of RAD retention, providers retain 2% pa of new RADs (capped at 5 years) • Independent review of accommodation supplement (Government funding for concessional residents) - by 1 July 2026 • Independent review of RADs - by 31 March 2030 ► Higher Everyday Living Fee (HELF) to replace Additional Services and Extra Services • Existing residents to be transitioned to HELF by 31 October 2026 ~$120 ~$70 Accommodation funding - $600,000 room, per resident per day1 DAP (non-concessional) Max. Accommodation Supplement (concessional) (1 July 2025) ___________________ 1 DAP calculated as $600,000 room price * 7.61% maximum permissible interest rate (1 October 2025) / 365 days ~$50 difference For personal use only
Page 13
Page 12 Acquisitions Rockpool ► Completed 1 September 2025 ► 4 premium homes in South-East Queensland ► 600 beds, 100% single ensuite rooms ► New homes - all opened in the last 6 years OC Health ► Expected to complete 1 December 2025 ► 2 homes in Drysdale and Torquay, Victoria ► 230 beds, 100% single ensuite rooms ► Both built or refurbished last 8 years For personal use only
Page 14
Page 13 Sustainable growth, higher quality beds 6,000 6,500 7,000 7,500 8,000 8,500 9,000 Portfolio bed growth since FY23 Acquisition of CPSM, QLD (5 homes & 644 beds) Acquisition of Ti Tree, VIC (2 homes & 262 beds) Camberwell greenfield development (112 beds) Acquisition of Rockpool, QLD (4 homes & 600 beds) 1,500+ net beds added over past 2 years through M&A, development and divestments enhancing scale and quality of portfolio Macleod, VIC divested (63 beds) Bulimba, QLD closed for redevelopment (150 beds) Weston, WA closed and sold (119 beds) Acquisition of Ocean Mist & Drysdale Grove, VIC1 (2 homes & 230 beds) ___________________ 1 As announced to ASX on 23 October 2025 - expected to complete on 1 December 2025 Acquisition Greenfield development Divestment / Closure For personal use only
Page 15
Page 14 Greenfield Development Pipeline Development State Beds Development Approval Status Toowong QLD 123 ✓ Construction commenced - H1 FY25 Carlingford NSW 101 ✓ Construction commenced - H2 FY25 Belrose NSW 99 ✓ Construction estimated to commence FY26 Bulimba QLD ~152 Construction estimated to commence FY27 Coburg VIC ~133 ✓ Construction estimated to commence FY27 Parkside SA ~156 Construction estimated to commence FY27 Newport VIC ~120 Construction estimated to commence FY27 Essendon VIC ~157 Construction estimated to commence FY28 Seaford VIC ~165 Construction estimated to commence FY28 Total Greenfield ~1,206 Artist’s impression - Regis Toowong, QLD Artist’s impression - Regis Carlingford, NSW For personal use only
Page 16
Page 15 7,600 600 230 10,000 FY25 Rockpool OC Health Developments Future acquisitions FY28 Regis Available Beds ~1,000 - 1,300 Targeting 10,000 beds ► Core business generates substantial free cash flow to fund greenfield development pipeline and strategic acquisitions ► Strategic acquisitions and greenfield sites to enhance scale, leverage technology investment and improve overall quality of portfolio ► Targeting margin expansion over time driven by additional funding (ie. RAD retention), improved economies of scale and RAD price increases ► Maintain financial discipline - continue to buy higher quality assets at attractive valuations, which are earnings accretive ► Drive growth in beds, revenue and earnings to enhance shareholder returns ~300 - 600 ~8,200 available beds today ~1,600 beds to build and acquire by FY281 Dec 25 For personal use only
Page 17
Page 16 FY26 Update Total occupied bed days ► Q1 FY26 - average mature homes occupancy was 95.8% ► 31 October 2025 - spot occupancy was 96.5% ► Regis Camberwell achieved full occupancy in November ► Q1 FY26 - $90m of net RAD inflows, included $31m from Regis Camberwell ► 30 September 2025 - Regis held $99 million of net cash ___________________ 1Average available beds for Q1 FY26 were 7,782. Spot available beds at 31 October 2025 were 8,154 210.1 215.3 225.1 226.7 226.7 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Average total care minutes (prpd) 95.5% 95.9% 95.5% 95.7% 95.8% Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Average Quarterly Occupancy - Mature homes (%) 653,936 659,229 651,453 651,499 671,303 406.4 436.0 442.9 446.5 451.6 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Average Aged Care revenue per occupied bed day ($) 96.5% For personal use only
Page 18
Page 17 Outlook Funding Environment M&A and Developments ► 1 November 2025 - New Aged Care Act • New funding legislation to improve longer-term provider returns ► Review of accommodation supplement by 31 July 2026 ► Complete and integrate Rockpool and OC Health acquisitions ► Specific M&A criteria drives disciplined approach • Acquire quality existing aged care businesses ► Ramp-up of Camberwell and Oxley ► 2 greenfield developments commenced Regis expects FY26 underlying EBITDA to be in the range of $130m - $135m1 Improved Workforce Availability ► Increased staffing levels reducing agency, turnover and training costs • Continuity of carer - improved resident outcomes ► Demographic shift with ageing population and increasing requirements of Baby Boomers ► Occupancy remains high and stable ► Strategic capex investment into select homes to improve occupancy over longer-term and support higher room prices Demand & Occupancy ___________________ 1 Underlying EBITDA is a non IFRS term, defined as earnings before interest, tax, depreciation and amortisation, excluding imputed income on RADs and Bonds and one-off items, and including operating lease expense For personal use only
Page 19
Formal Business For personal use only
Page 20
Item 1 Annual Financial Report For personal use only
Page 21
Item 2 Re-election of Directors 2.1 Ian Roberts 2.2 Sally Freeman For personal use only
Page 22
Item 2.1 Re-election of Ian Roberts For personal use only
Page 23
Page 22 Proxy Position: Item 2.1 Re-election of Ian Roberts as Director Proxy position In Favour Undirected proxies* Open Against Total Valid Available Votes As a % of Issued Capital Abstain Votes 254,609,192 70,639 4,060,900 258,740,731 85.55% 43,294 Holders 82 8 15 1 Percentage 98.40 0.03 1.57 * Undirected proxies for Chair of the meeting to vote (Chair will vote “in favour”) For personal use only
Page 24
Item 2.2 Re-election of Sally Freeman For personal use only
Page 25
Page 24 Proxy Position: Item 2.2 Re-election of Sally Freeman as Director Proxy position In Favour Undirected proxies* Open Against Total Valid Available Votes As a % of Issued Capital Abstain Votes 255,333,102 70,639 3,336,990 258,740,731 85.55% 43,294 Holders 75 8 23 1 Percentage 98.68 0.03 1.29 * Undirected proxies for Chair of the meeting to vote (Chair will vote “in favour”) For personal use only
Page 26
Item 3 Adoption of the Remuneration Report For personal use only
Page 27
Page 26 Proxy Position: Item 3 Adoption of the Remuneration Report Proxy position In Favour Undirected proxies* Open Against Total Valid Available Votes As a % of Issued Capital Abstain Votes 174,183,277 71,639 1,858,315 176,113,231 58.23% 442,350 Holders 59 10 27 5 Percentage 98.90 0.04 1.06 * Undirected proxies for Chair of the meeting to vote (Chair will vote “in favour”) For personal use only
Page 28
Item 4 Approval of FY26 grant of Performance Rights to the MD/CEO under the LTI Plan For personal use only
Page 29
Page 28 Proxy Position: Item 4 Approval of FY26 grant of Performance Rights to the MD/CEO under the LTI Plan Proxy position In Favour Undirected proxies* Open Against Total Valid Available Votes As a % of Issued Capital Abstain Votes 175,841,501 71,389 239,236 176,152,126 58.24% 82,347,629 Holders 54 10 33 4 Percentage 99.82 0.04 0.14 * Undirected proxies for Chair of the meeting to vote (Chair will vote “in favour”) For personal use only
Page 30
Item 5 Reinsertion of the proportional takeover approval provision For personal use only
Page 31
Page 30 Proxy Position: Item 5 Reinsertion of the proportional takeover approval provision Proxy position In Favour Undirected proxies* Open Against Total Valid Available Votes As a % of Issued Capital Abstain Votes 258,126,658 92,481 544,125 258,763,264 85.55% 20,761 Holders 71 13 14 4 Percentage 99.75 0.04 0.21 * Undirected proxies for Chair of the meeting to vote (Chair will vote “in favour”) For personal use only
Page 32
Meeting Concludes The detailed results of the polls will be announced on the Company’s website and ASX announcement platform later today For personal use only
Page 33
Page 32 Important Information and Disclaimer This Presentation contains summary information about the current activities of Regis Healthcare Limited and its controlled entities (Regis Healthcare or the Group). It should be read in conjunction with the Group's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), including the Full-Year Financial Report and associated Media Release, which are available at www.asx.com.au. No member of Regis Healthcare gives any warranties in relation to the statements or information contained in this Presentation. The information contained in this Presentation is of a general nature and has been prepared by the Group in good faith and with due care but no representation or warranty, express or implied, is provided in relation to the accuracy or completeness of the information. No responsibility or liability is accepted for any errors, misstatements or omissions. To the extent permitted by law, neither Regis Healthcare nor the Group, nor their Directors, employees or agents or any other person accepts any liability arising from its or their fault or negligence, for any direct, indirect or consequential loss arising from use of this information pack or its contents or otherwise in connection with it. This Presentation is for information purposes only and is not a prospectus, product disclosure statement or other disclosure or offering document under Australian or any other law. This Presentation does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither this Presentation nor anything contained in it shall form the basis of any contract or commitment. This Presentation is not a recommendation to acquire Regis Healthcare shares. The information provided in this Presentation is not financial product advice and has been prepared without taking into account any recipient's investment objectives, financial circumstances or particular needs, and should not be considered to be comprehensive or to comprise all the information which a recipient may require in order to make an investment decision regarding Regis Healthcare shares. Recipients should seek their own independent financial advice. Neither Regis Healthcare nor any other person warrants or guarantees the future performance of Regis Healthcare shares nor any return on any investment made in Regis Healthcare shares. This Presentation may contain certain forward-looking statements. The words 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'could', 'may', 'target', 'plan' and other similar expressions are intended to identify forward- looking statements. Indications of, and guidance on, financial position and performance are also forward-looking statements. Any forecasts or other forward-looking statements contained in this Presentation are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Such factors and uncertainties may include, without limitation, changes in laws, regulation and regulatory activity, sector reforms including funding and care minutes reforms, staffing availability and costs and potential for further COVID-19 and similar outbreaks. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Group and they may cause actual results to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. You are cautioned not to place undue reliance on forward-looking statements. Except as required by law or regulation (including the ASX Listing Rules), Regis Healthcare has no obligation to update these forward-looking statements. Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. All dollar values are in Australian dollars (A$) unless otherwise stated. Non-IFRS Financial Information This presentation uses Non-IFRS financial information including capital expenditure, underlying EBITDA, underlying EBIT, underlying NPAT, operating cash flow, net cash and net debt. These terms are Non-IFRS measures used by the Group, the investment community and Regis Healthcare’s Australian peers with similar business portfolios. Regis Healthcare uses these measures for its internal management reporting as it better reflects what Regis Healthcare considers to be the underlying performance of the Group. For personal use only
Page 34
Annual General Meeting 18 November 2025 For personal use only